{"DataElement":{"publicId":"6148865","version":"1","preferredName":"Follow-up Patient Visit Malignant Neoplasm Occurrence Type","preferredDefinition":"The type of patient follow-up visit with regards to cancer occurrence.","longName":"VIS_TP","context":"CCTG","contextVersion":"1","DataElementConcept":{"publicId":"6148860","version":"1","preferredName":"Follow-up Patient Visit Malignant Neoplasm Occurrence","preferredDefinition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done._A visit by a patient or study participant to a medical professional._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._An instance of something happening, such as an event or incident.","longName":"6148857v1.0:6148858v1.0","context":"CCTG","contextVersion":"1","ObjectClass":{"publicId":"6148857","version":"1","preferredName":"Follow-up Patient Visit","preferredDefinition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.:A visit by a patient or study participant to a medical professional.","longName":"C16033:C39564","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follow-Up","conceptCode":"C16033","definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient Visit","conceptCode":"C39564","definition":"A visit by a patient or study participant to a medical professional.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6851D30C-E6BD-0EED-E053-F662850A2BDE","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6148858","version":"1","preferredName":"Malignant Neoplasm Occurrence","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.:An instance of something happening, such as an event or incident.","longName":"C9305:C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6851D30C-E6CE-0EED-E053-F662850A2BDE","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6851D30C-E6DF-0EED-E053-F662850A2BDE","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"TAYLORT","dateModified":"2018-11-21","changeDescription":"11-21-18 TT released/CWinch. 3/26/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6148851","version":"1","preferredName":"Visit Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6148851v1.0","context":"CCTG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"After distant recurrence","valueDescription":"Post Recurrent Disease, Distant Site","ValueMeaning":{"publicId":"6148852","version":"1","preferredName":"Post Recurrent Disease, Distant Site","longName":"6148852","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.: Recurrence of symptoms of a disease, at a site different and away from the original site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease, Distant Site","conceptCode":"C55073","definition":"Recurrence of symptoms of a disease, at a site different and away from the original site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"684510F6-79C8-5C79-E053-F662850A7DED","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"684510F6-79E1-5C79-E053-F662850A7DED","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"After local-regional breast cancer recurrence but no distant recurrence","valueDescription":"Post Local-Regional Breast Carcinoma Recurrent Malignant Neoplasm Without Recurrent Disease, Distant Site","ValueMeaning":{"publicId":"6148853","version":"1","preferredName":"Post Local-Regional Breast Carcinoma Recurrent Malignant Neoplasm Without Recurrent Disease, Distant Site","longName":"6148853","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.: Of or belonging to both a local and regional area of the body.: A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.: The reemergence of a malignant neoplasm after a period of remission.: Used to indicate the absence or lack of something or someone.: Recurrence of symptoms of a disease, at a site different and away from the original site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Local-Regional","conceptCode":"C25388","definition":"Of or belonging to both a local and regional area of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Recurrent Malignant Neoplasm","conceptCode":"C4813","definition":"The reemergence of a malignant neoplasm after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease, Distant Site","conceptCode":"C55073","definition":"Recurrence of symptoms of a disease, at a site different and away from the original site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"684510F6-79F2-5C79-E053-F662850A7DED","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"684510F6-7A0B-5C79-E053-F662850A7DED","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Prior to any breast cancer recurrence","valueDescription":"Prior To Any Breast Carcinoma Recurrence","ValueMeaning":{"publicId":"6345427","version":"1","preferredName":"Prior To Any Breast Carcinoma Recurrence","longName":"6345427","preferredDefinition":"Earlier in time or order.: Used as a function word to indicate direction, purpose, or movement.: One, some, every, or all without specification.: A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.: To come back or to return.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Any","conceptCode":"C81168","definition":"One, some, every, or all without specification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrence","conceptCode":"C3352","definition":"Happening again (especially at regular intervals).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"700ABF02-714F-2A19-E053-F662850A3E39","latestVersionIndicator":"Yes","beginDate":"2018-07-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-03","modifiedBy":"ONEDATA","dateModified":"2018-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"700ABF02-7168-2A19-E053-F662850A3E39","beginDate":"2018-07-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-03","modifiedBy":"ONEDATA","dateModified":"2018-07-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"684510F6-79AE-5C79-E053-F662850A7DED","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"TAYLORT","dateModified":"2018-11-21","changeDescription":"11-21-18 TT released/CWinch. 3/25/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Visit type","type":"Preferred Question Text","description":"Visit type","url":null,"context":"CCTG"}],"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6850673E-D13E-0BA9-E053-F662850A7713","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"TAYLORT","dateModified":"2018-11-21","changeDescription":"11-21-18 TT released/CWinch. 3/26/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}